Triglav Investments D.O.O. Boosts Holdings in Pfizer Inc. $PFE

Triglav Investments D.O.O. lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 31.3% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 415,792 shares of the biopharmaceutical company’s stock after buying an additional 99,092 shares during the quarter. Triglav Investments D.O.O.’s holdings in Pfizer were worth $10,353,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Fideuram Asset Management Ireland dac purchased a new stake in shares of Pfizer during the fourth quarter worth about $2,111,000. Brickwood Asset Management LLP boosted its position in shares of Pfizer by 21.7% in the fourth quarter. Brickwood Asset Management LLP now owns 26,169 shares of the biopharmaceutical company’s stock worth $652,000 after acquiring an additional 4,670 shares during the last quarter. National Pension Service lifted its position in Pfizer by 3.9% during the fourth quarter. National Pension Service now owns 13,439,182 shares of the biopharmaceutical company’s stock valued at $334,636,000 after buying an additional 498,289 shares in the last quarter. Linscomb Wealth Inc. lifted its position in Pfizer by 1.2% during the fourth quarter. Linscomb Wealth Inc. now owns 257,326 shares of the biopharmaceutical company’s stock valued at $6,407,000 after buying an additional 3,063 shares in the last quarter. Finally, Weaver Consulting Group lifted its position in Pfizer by 17.3% during the fourth quarter. Weaver Consulting Group now owns 11,189 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 1,652 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced a major global oncology collaboration with Innovent Biologics worth up to $10.5 billion. The deal gives Pfizer access to 12 early-stage cancer programs and expands its cancer pipeline, which investors may see as a long-term growth driver. Article Title
• Positive Sentiment: Pfizer reported seven-year follow-up data from its LORBRENA CROWN trial, showing the longest progression-free survival reported to date in advanced ALK-positive non-small cell lung cancer. Strong late-stage clinical evidence can support the drug’s commercial outlook and reinforce Pfizer’s oncology franchise. Article Title
• Positive Sentiment: Several reports highlighted progress in Pfizer’s clinical pipeline, including updates tied to lung cancer and obesity programs. Investors often reward pipeline milestones because they can improve future revenue potential and diversify growth beyond existing products. Article Title
• Neutral Sentiment: Commentary on insider activity suggested Pfizer insiders are not buying shares aggressively at current levels, but the article framed that as a lack of negative signal rather than a warning sign. This is more of a valuation/sentiment note than a direct catalyst. Article Title
• Neutral Sentiment: Additional items referenced early-stage trial updates and a real-world lung cancer study on dacomitinib. These are constructive for the pipeline, but they are still early and likely less material than the Innovent deal or the LORBRENA data. Article Title

Analyst Ratings Changes

A number of research analysts have recently commented on PFE shares. Morgan Stanley boosted their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Friday, April 10th. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. UBS Group reiterated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research note on Wednesday. BMO Capital Markets reiterated an “outperform” rating and set a $30.00 target price on shares of Pfizer in a research note on Monday, March 9th. Finally, Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eleven have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $28.82.

Pfizer Stock Up 0.2%

PFE stock opened at $26.18 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. Pfizer Inc. has a 1-year low of $23.06 and a 1-year high of $28.75. The firm has a fifty day moving average price of $26.77 and a two-hundred day moving average price of $26.28. The firm has a market cap of $149.23 billion, a price-to-earnings ratio of 19.99 and a beta of 0.35.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts predict that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. Pfizer’s dividend payout ratio is currently 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.